Queen Mary University of London spin-out Activiomics enters into research programme with Kyowa Hakko Kirin.

Life sciences firm Activiomics has built on its contract research agreement with Japan-based pharmaceutical firm Kyowa Hakko Kirin (KHK) by entering into a new research programme.

The London-based Queen Mary University of London spin-out will apply its cell signalling TIQUAS platform to lead compounds supplied by KHK.

Activiomics has received $805k in venture funding. The financing came from a 2011 venture round, backed solely by commercialisation firm the IP Group.

Hiroshi Okazaki, managing officer at Kyowa Hakko Kirin, said: “We…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?